Identification of tissue of origin in body fluid specimens using a gene expression microarray assay
- 29 June 2011
- journal article
- research article
- Published by Wiley in Cancer Cytopathology
- Vol. 120 (1) , 62-70
Abstract
BACKGROUND: Body fluid specimens may be the first and only pathologic specimen for clinical evaluation in metastatic cancer cases. The challenge of identifying the tissue of origin in metastatic cancer has led to the emergence of molecular‐based assays, such as the microarray‐based Pathwork Tissue of Origin gene expression test. The ability to use body fluid specimens in this test would be valuable in providing diagnoses to cancer patients without clearly identifiable primary sites. In the current study, the authors evaluated the Tissue of Origin Test for use with malignant effusion specimens.METHODS: A total of 27 metastasis‐positive body fluid specimens from different body sites, including pleural, ascites, pericardial, and pelvic wash fluids, were obtained from patients with known diagnoses. Nine specimens from nonmalignant body fluids were included as controls. RNA was extracted from formalin‐fixed, paraffin‐embedded (FFPE) tissue and gene expression analysis was performed with the Tissue of Origin Test.RESULTS: Seventeen of 27 metastasis‐positive samples were non‐necrotic with ≥60% tumor and yielded sufficient RNA. Of these samples, 94.1% (16 of 17) were in agreement with the available diagnosis. Of the 9 negative control samples evaluated, 7 (77.8%) demonstrated microarray expression profiles most similar to lymphoma, which is consistent with the predominance of inflammatory cells in these specimens.CONCLUSIONS: The results of the current study demonstrated that FFPE cell blocks from cytologic body fluid specimens yield adequate diagnostic material for the Pathwork test and can be used in the workup of patients with unknown primary tumors. Cancer (Cancer Cytopathol) 2012. © 2011 American Cancer Society.Keywords
This publication has 11 references indexed in Scilit:
- Validation and Reproducibility of a Microarray-Based Gene Expression Test for Tumor Identification in Formalin-Fixed, Paraffin-Embedded SpecimensThe Journal of Molecular Diagnostics, 2011
- Multicenter Validation of a 1,550-Gene Expression Profile for Identification of Tumor Tissue of OriginJournal of Clinical Oncology, 2009
- MicroRNAs accurately identify cancer tissue originNature Biotechnology, 2008
- Interlaboratory Performance of a Microarray-Based Gene Expression Test to Determine Tissue of Origin in Poorly Differentiated and Undifferentiated CancersThe Journal of Molecular Diagnostics, 2008
- Switching benchmarks in cancer of unknown primary: From autopsy to microarrayEuropean Journal of Cancer, 2007
- Surgical Management of Metastatic Peritoneal or Pleural DiseaseSeminars in Oncology, 2007
- Prognosis of sub-types of cancer of unknown primary (CUP) compared to metastatic cancerJournal of Clinical Oncology, 2007
- Molecular Classification of Human Cancers Using a 92‐Gene Real-Time Quantitative Polymerase Chain Reaction AssayArchives of Pathology & Laboratory Medicine, 2006
- Cancer of unknown primary (CUP)Critical Reviews in Oncology/Hematology, 2005
- The malignant pleural effusion. A review of cytopathologic diagnoses of 584 specimens from 472 consecutive patientsCancer, 1985